BACKGROUND: Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by excessive daytime sleepiness and repetitive upper airway obstruction episodes during sleep. Clinically, obesity is a major risk factor for developing OSAS. However, OSAS has been associated with hormonal and metabolic alterations that could predispose patients to obesity. The aim of this study was to investigate the independent role of apneas and obesity on plasma levels of metabolic hormones (adiponectin, ghrelin, and leptin) in patients with OSAS. METHODS: We have studied patients with OSAS and controls with and without obesity. All patients were male, had an apnea-hypopnea index of 20/h or greater, and were eligible for nasal continuous positive airway pressure (nCPAP) treatment. Patients were considered obese (n = 28) when their BMI was higher than 30 kg/m(2) and non-obese (n = 21) when it was lower than 27 kg/m(2). Non-obese control subjects (n = 20) were non-snorers with a normal cardiorespiratory sleep study, while obese control subjects (n = 10) were recruited from those obese subjects who were visited in our sleep unit and for whom OSAS was excluded by full polysomnography. A single blood sample was obtained from an antecubital vein in all participants after the completion of the nocturnal sleep laboratory recording. Plasma leptin, adiponectin, and ghrelin levels were determined by radioimmunoassay. RESULTS: The adiponectin, ghrelin, and leptin plasma levels were similar in both patients and controls. There were differences in leptin and adiponectin plasma levels between the obese and non-obese in both patient and control groups. In the case of ghrelin, differences between obese and non-obese subjects were only seen in patients. There were no significant differences in hormone levels between the obese controls and obese patients or between non-obese controls and non-obese patients. After 3 months of nCPAP treatment, adiponectin levels decreased significantly both in obese and non-obese patients, and leptin levels decreased in obese patients. Finally, nCPAP did not reduce ghrelin in either obese or non-obese patients. CONCLUSIONS: The basal levels of leptin, adiponectin, and ghrelin were mostly associated with obesity. We found that sleep apnea was not a determinant factor in leptin, adiponectin, and ghrelin hormonal levels. Interestingly, nCPAP treatment diminishes leptin in obese OSA patients and adiponectin levels in obese and non-obese patients with OSAS.
BACKGROUND: Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by excessive daytime sleepiness and repetitive upper airway obstruction episodes during sleep. Clinically, obesity is a major risk factor for developing OSAS. However, OSAS has been associated with hormonal and metabolic alterations that could predispose patients to obesity. The aim of this study was to investigate the independent role of apneas and obesity on plasma levels of metabolic hormones (adiponectin, ghrelin, and leptin) in patients with OSAS. METHODS: We have studied patients with OSAS and controls with and without obesity. All patients were male, had an apnea-hypopnea index of 20/h or greater, and were eligible for nasal continuous positive airway pressure (nCPAP) treatment. Patients were considered obese (n = 28) when their BMI was higher than 30 kg/m(2) and non-obese (n = 21) when it was lower than 27 kg/m(2). Non-obese control subjects (n = 20) were non-snorers with a normal cardiorespiratory sleep study, while obese control subjects (n = 10) were recruited from those obese subjects who were visited in our sleep unit and for whom OSAS was excluded by full polysomnography. A single blood sample was obtained from an antecubital vein in all participants after the completion of the nocturnal sleep laboratory recording. Plasma leptin, adiponectin, and ghrelin levels were determined by radioimmunoassay. RESULTS: The adiponectin, ghrelin, and leptin plasma levels were similar in both patients and controls. There were differences in leptin and adiponectin plasma levels between the obese and non-obese in both patient and control groups. In the case of ghrelin, differences between obese and non-obese subjects were only seen in patients. There were no significant differences in hormone levels between the obese controls and obesepatients or between non-obese controls and non-obesepatients. After 3 months of nCPAP treatment, adiponectin levels decreased significantly both in obese and non-obesepatients, and leptin levels decreased in obesepatients. Finally, nCPAP did not reduce ghrelin in either obese or non-obesepatients. CONCLUSIONS: The basal levels of leptin, adiponectin, and ghrelin were mostly associated with obesity. We found that sleep apnea was not a determinant factor in leptin, adiponectin, and ghrelin hormonal levels. Interestingly, nCPAP treatment diminishes leptin in obese OSA patients and adiponectin levels in obese and non-obesepatients with OSAS.
Authors: Antonia Barceló; Ferrán Barbé; Elena Llompart; Lola R Mayoralas; Antoni Ladaria; Margalida Bosch; Alvar G N Agustí Journal: Am J Med Date: 2004-07-15 Impact factor: 4.965
Authors: K Chin; K Shimizu; T Nakamura; N Narai; H Masuzaki; Y Ogawa; M Mishima; T Nakamura; K Nakao; M Ohi Journal: Circulation Date: 1999-08-17 Impact factor: 29.690
Authors: M Aizawa-Abe; Y Ogawa; H Masuzaki; K Ebihara; N Satoh; H Iwai; N Matsuoka; T Hayashi; K Hosoda; G Inoue; Y Yoshimasa; K Nakao Journal: J Clin Invest Date: 2000-05 Impact factor: 14.808
Authors: B Masserini; P S Morpurgo; F Donadio; C Baldessari; R Bossi; P Beck-Peccoz; E Orsi Journal: J Endocrinol Invest Date: 2006-09 Impact factor: 4.256
Authors: Trent A Hargens; Stephen G Guill; Anthony S Kaleth; Sharon M Nickols-Richardson; Larry E Miller; Donald Zedalis; John M Gregg; Frank Gwazdauskas; William G Herbert Journal: Sleep Breath Date: 2012-04-24 Impact factor: 2.816
Authors: E S Arnardottir; G Maislin; N Jackson; R J Schwab; B Benediktsdottir; K Teff; S Juliusson; A I Pack; T Gislason Journal: Int J Obes (Lond) Date: 2012-09-11 Impact factor: 5.095